Law Offices of Howard G. Smith announces that it is investigating potential claims against the board of directors of Clinical Data, Inc. (“Clinical Data” or the “Company”) (NASDAQ:CLDA), related to the Company’s agreement to be acquired by Forest Laboratories, Inc. The proposed transaction is valued at approximately $1.2 billion.

Under the terms of the definitive merger agreement entered into by the parties, Clinical Data shareholders would receive a cash payment of $30.00 per share for each share they own of the Company’s stock, plus contingent consideration of up to $6.00 per share that may be paid upon achievement of certain commercial milestones related to Viibryd (vilazodone HCL tablets), a treatment for adults with major depressive disorder which was developed by Clinical Data and approved by the U.S. Food and Drug Administration on January 21, 2011. The proposed transaction is expected to be completed in the second quarter of 2011. The investigation concerns possible breaches of fiduciary duty and other violations of law related to approval of the proposed transaction by Clinical Data’s board of directors.

If you own shares of Clinical Data, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll Free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at http://www.howardsmithlaw.com.

Clinical Data (NASDAQ:CLDA)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025 Plus de graphiques de la Bourse Clinical Data
Clinical Data (NASDAQ:CLDA)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025 Plus de graphiques de la Bourse Clinical Data